UTMD Utah Medical Products Inc
Price (delayed)
$56
Market cap
$183.78M
P/E Ratio
14.14
Dividend/share
$1.21
EPS
$3.96
Enterprise value
$101.09M
Utah Medical Products, Inc. with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized
Highlights
UTMD's P/E is 34% below its 5-year quarterly average of 21.3 and 9% below its last 4 quarters average of 15.6
The debt is down by 6% QoQ and by 4.4% YoY
Utah Medical Products's quick ratio has decreased by 14% from the previous quarter but it has increased by 13% YoY
The gross profit has declined by 20% year-on-year and by 7% since the previous quarter
UTMD's revenue is down by 19% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of UTMD
Market
Valuations
Earnings
Shares outstanding
3.28M
Market cap
$183.78M
Enterprise value
$101.09M
Price to earnings (P/E)
14.14
Price to book (P/B)
1.62
Price to sales (P/S)
4.64
EV/EBIT
6.02
EV/EBITDA
5.14
EV/Sales
2.47
Revenue
$40.9M
Gross profit
$24.14M
Operating income
$13.59M
Net income
$13.87M
EBIT
$16.8M
EBITDA
$19.65M
Free cash flow
$14.63M
Per share
Balance sheet
Liquidity
EPS
$3.96
EPS diluted
$3.96
Free cash flow per share
$4.31
Book value per share
$34.62
Revenue per share
$12.06
TBVPS
$31.28
Total assets
$122.54M
Total liabilities
$5.11M
Debt
$282,000
Equity
$117.43M
Working capital
$92.57M
Debt to equity
0
Current ratio
25.64
Quick ratio
23.18
Net debt/EBITDA
-4.21
Margins
Efficiency
Dividend
EBITDA margin
48%
Gross margin
59%
Net margin
33.9%
Operating margin
33.2%
Return on assets
10.7%
Return on equity
11.2%
Return on invested capital
86%
Return on capital employed
14.1%
Return on sales
41.1%
Dividend yield
2.16%
DPS
$1.21
Payout ratio
30.6%
UTMD stock price
How has the Utah Medical Products stock price performed over time
Intraday
-0.07%
1 week
-1.32%
1 month
-6.06%
1 year
-20.83%
YTD
-8.9%
QTD
-0.07%
Financial performance
How have Utah Medical Products's revenue and profit performed over time
Revenue
$40.9M
Gross profit
$24.14M
Operating income
$13.59M
Net income
$13.87M
Gross margin
59%
Net margin
33.9%
The gross profit has declined by 20% year-on-year and by 7% since the previous quarter
The operating income has contracted by 19% YoY and by 7% from the previous quarter
UTMD's revenue is down by 19% year-on-year and by 7% since the previous quarter
UTMD's net income is down by 17% YoY and by 9% from the previous quarter
Growth
What is Utah Medical Products's growth rate over time
Valuation
What is Utah Medical Products stock price valuation
P/E
14.14
P/B
1.62
P/S
4.64
EV/EBIT
6.02
EV/EBITDA
5.14
EV/Sales
2.47
UTMD's P/E is 34% below its 5-year quarterly average of 21.3 and 9% below its last 4 quarters average of 15.6
UTMD's EPS is down by 14% year-on-year and by 7% since the previous quarter
UTMD's price to book (P/B) is 40% lower than its 5-year quarterly average of 2.7 and 15% lower than its last 4 quarters average of 1.9
The equity has contracted by 8% YoY and by 5% from the previous quarter
The stock's P/S is 28% below its 5-year quarterly average of 6.4 and 11% below its last 4 quarters average of 5.2
UTMD's revenue is down by 19% year-on-year and by 7% since the previous quarter
Efficiency
How efficient is Utah Medical Products business performance
UTMD's ROE is down by 17% YoY and by 7% from the previous quarter
Utah Medical Products's return on assets has decreased by 16% YoY and by 7% QoQ
Utah Medical Products's ROIC has decreased by 16% YoY and by 8% from the previous quarter
UTMD's ROS is up by 2.8% year-on-year
Dividends
What is UTMD's dividend history
DPS
$1.21
Dividend yield
2.16%
Payout ratio
30.6%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Utah Medical Products financials performed over time
Utah Medical Products's total liabilities has decreased by 28% YoY and by 7% QoQ
The current ratio has grown by 14% YoY but it has contracted by 13% from the previous quarter
The debt is 100% lower than the equity
The equity has contracted by 8% YoY and by 5% from the previous quarter
The debt is down by 6% QoQ and by 4.4% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.